

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/882,774	06/14/2001		Michael E. Houston	003592-007	9292
26181	7590 03/29/2005			EXAMINER	
FISH & RICHARDSON P.C. 3300 DAIN RAUSCHER PLAZA				ZEMAN, ROBERT A	
MINNEAPOLIS, MN 55402				ART UNIT	PAPER NUMBER
	-			1645	

DATE MAILED: 03/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./CONTROL NO.  09/882,774	FILING DATE	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.	
	1, 1		EXAMINER	
		Rob	Robert A. Zeman	
		ART UNI	T PAPER	
• .		164	5	

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

Robert Zum

Application No.: 09/882,774

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

J. 12 "

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. 3 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	<ol> <li>This application does not contain, as a separate part of the disclosure on paper copy, a ASequence Listing≅ as required by 37 C.F.R. 1.821(c).</li> </ol>
	<ol> <li>A copy of the ASequence Listing≅ in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).</li> </ol>
	4. A copy of the ASequence Listing≅ in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up ARaw Sequence Listing.≅
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the ASequence Listing≅ is not the same as the computer readable from of the ASequence Listing≅ as required by 37 C.F.R. 1.821(e).
	7. Other: The specification, appendix to the specification and Figure 6 contain sequences without the required sequence identifiers (see pages 42, 50 and 58 for examples).
App	olicant Must Provide:
	An initial or <u>substitute</u> computer readable form (CRF) copy of the ASequence Listing≅.
	An initial or <u>substitute</u> paper copy of the ASequence Listing≅, as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212
Pate	entIn Software Program Support Technical Assistance703-287-0200
	To Purchase PatentIn Software703-306-2600
	10 Fulchase Fateritin Software